Latin America Liver Disease Therapeutics Market Size & Outlook
Related Markets
Latin America liver disease therapeutics market highlights
- The Latin America liver disease therapeutics market generated a revenue of USD 939.8 million in 2024.
- The market is expected to grow at a CAGR of 7.2% from 2025 to 2033.
- In terms of segment, antiviral drugs was the largest revenue generating product in 2024.
- Targeted Therapy is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Brazil is expected to register the highest CAGR from 2025 to 2033.
Latin America data book summary
| Market revenue in 2024 | USD 939.8 million |
| Market revenue in 2033 | USD 1,752.6 million |
| Growth rate | 7.2% (CAGR from 2025 to 2033) |
| Largest segment | Antiviral drugs |
| Fastest growing segment | Targeted Therapy |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antiviral Drugs, Vaccines, Chemotherapy (Cytotoxic Drugs), Targeted Therapy, Immunosuppressants, Immunoglobulins, Corticosteroids, Other Products |
| Key market players worldwide | Gilead Sciences Inc, AbbVie Inc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc, Sanofi SA, GSK PLC |
Other key industry trends
- In terms of revenue, Latin America region accounted for 4.6% of the global liver disease therapeutics market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 10,249.5 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Liver Disease Therapeutics Market Scope
Liver Disease Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Merck & Co., Inc. | View profile | - | - | - |
| Takeda Pharmaceutical Company Limited | View profile | - | - | - |
| Bristol-Myers Squibb Company | View profile | - | - | - |
| Novartis AG | View profile | - | - | - |
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| Gilead Sciences Inc | View profile | 18000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | https://www.gilead.com |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Latin America liver disease therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liver disease therapeutics market will help companies and investors design strategic landscapes.
Antiviral drugs was the largest segment with a revenue share of 40.34% in 2024. Horizon Databook has segmented the Latin America liver disease therapeutics market based on antiviral drugs, vaccines, chemotherapy (cytotoxic drugs), targeted therapy, immunosuppressants, immunoglobulins, corticosteroids, other products covering the revenue growth of each sub-segment from 2021 to 2033.
Latin America’s liver disease therapeutics market is developing steadily, driven by the growing burden of hepatitis B and C, non-alcoholic fatty liver disease (NAFLD), and alcohol-related liver conditions. Rising obesity rates and increased alcohol consumption have intensified the prevalence of liver disorders across countries like Brazil, Mexico, and Argentina.
Public health initiatives, such as expanded hepatitis vaccination campaigns and awareness programs, are enhancing early diagnosis and treatment. Access to direct-acting antivirals (DAAs) and generic formulations has improved affordability, particularly through regional partnerships and government-subsidized programs.
Reasons to subscribe to Latin America liver disease therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Latin America liver disease therapeutics market databook
-
Our clientele includes a mix of liver disease therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America liver disease therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America liver disease therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Latin America liver disease therapeutics market size, by country, 2021-2033 (US$M)
Latin America Liver Disease Therapeutics Market Outlook Share, 2024 & 2033 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
